Rockefeller Capital Management
CRDF icon

Rockefeller Capital Management’s Cardiff Oncology CRDF Stock Holding History

Rockefeller Capital Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26K Sell
20,000
-36,500
-65% -$58K ﹤0.01% 3648
2026
Q1 		$91.5K Hold
56,500
– – ﹤0.01% 2929
2025
Q4 		$159K Sell
56,500
-6,000
-10% -$13.9K ﹤0.01% 2485
2025
Q3 		$129K Buy
+62,500
New +$173K ﹤0.01% 2445
2022
Q4 		– Sell
-163
Closed – – 3894
2022
Q3 		$0 Hold
163
– – ﹤0.01% 3949
2022
Q2 		$0 Buy
163
+156
+2,229% +$261 ﹤0.01% 4140
2022
Q1 		$0 Buy
7
+1
+17% +$4 ﹤0.01% 3893
2021
Q4 		$0 Buy
+6
New +$36 ﹤0.01% 3799
2021
Q3 		– Sell
-882
Closed -$5K – 3709
2021
Q2 		$5K Sell
882
-353
-29% -$2.99K ﹤0.01% 3022
2021
Q1 		$11K Buy
1,235
+1,061
+610% +$12.9K ﹤0.01% 2535
2020
Q4 		$3K Sell
174
-6,880
-98% -$121K ﹤0.01% 2546
2020
Q3 		$100K Buy
+7,054
New +$46.6K ﹤0.01% 1253

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Rockefeller Capital Management's CRDF Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Cardiff Oncology (CRDF) stake by 65% in Q2 2026, selling an estimated $58K and leaving 20,000 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #3648.

Rockefeller Capital Management first reported a position in CRDF in Q3 2020 and has held it in 12 quarters since. The position peaked at $159K in Q4 2025. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Rockefeller Capital Management held 20,000 shares of Cardiff Oncology worth $26K as of Q2 2026.
  • Rockefeller Capital Management sold 36,500 Cardiff Oncology shares in Q2 2026, an estimated $58K.
  • Cardiff Oncology made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3648 holding.
  • Rockefeller Capital Management first reported a position in Cardiff Oncology in Q3 2020 and has held it in 12 quarters since.
  • Rockefeller Capital Management's Cardiff Oncology position peaked at $159K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.